Plasma Protease C1-inhibitor Treatment - Preclinical safety aspects on the potential prothrombotic risk, Market will grow at 18.2% CAGR, to be valued at US$ 10,603.4 Million by 2027
Global Plasma Protease C1-Inhibitor Treatment Market
Hereditary angioedema is a disorder characterized by low levels of functional C1 inhibitor protein and results in recurrent attacks of severe swelling. The swelling usually affects the face, legs, arms, airway, and intestinal tract. Plasma protease C1-inhibitors such as Berinet, Kalbitor, Firazyr, and Cinryze have been approved for the prophylactic and treatment of hereditary angioedema. It also help regulate important physiological pathways such as generation of kinins, fibrinolysis, blood coagulation, and complement activation. C1 inhibitor also inhibits kallikrein and chymotrypsin.
Get Sample PDF Including COVID-19 Impact Analysis: https://www.coherentmarketinsights.com/insight/request-pdf/4262
Biopharmaceutical companies are focused on developing effective plasma protease C1-inhibitor therapies or drugs to treat various health conditions such as diabetic macular edema (DME), hereditary angioedema (HAE) and others, which in turn, is expected to propel the global plasma protease C1-inhibitor treatment market growth over the forecast period. For instance, in September 2019, Oxurion released positive topline data from a phase 1 study of THR-149, a plasma kallikrein inhibitor for the treatment of diabetic macular edema (DME).
Moreover, in December 2019, KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced results of the Phase 2 clinical trial evaluating the use of KVD001 in patients with diabetic macular edema (DME).
Furthermore, market players are adopting various inorganic growth strategies, such as partnership and collaboration, to develop innovative protease C1-inhibitor treatment, which is expected to augment the growth of the global plasma protease C1-inhibitor treatment market. For instance, in October 2017, KalVista Pharmaceuticals, Inc. entered into a collaboration agreement with Merck, known as MSD outside the U.S. and Canada for KVD001 (investigational plasma kallikrein inhibitors). The company’s investigational intravitreal (IVT) injection candidate is currently in development for potential treatment of diabetic macular edema (DME).
Tailored Information as per niche requirement:
LIMITED TIME OFFER - Hurry Up!
Exclusive offer!!! Purchase the report at a discounted rate!!!
Get Discount For Buyers UPTO 30% OFF On Any Research Report
Buy Now with Discount for Premium Report 2021: https://www.coherentmarketinsights.com/promo/buynow/4262
The rare occurrence of hereditary angioedema and lower diagnosis rate is expected to hamper growth of the global plasma protease c1-inhibitor treatment market.
By Drug Type
- Kallikrein Inhibitor
- Selective Bradykinin B2 Receptor Antagonist
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- North America
- Latin America
- Asia Pacific
- Middle East and Africa
View Press Release for More Information @ https://www.coherentmarketinsights.com/press-release/plasma-protease-c1-inhibitor-treatment-market-3525
North American is expected to witness robust growth in the global plasma protease C1-inhibitor treatment market due to increasing approvals of novel therapies in the region. For instance, in 2014, Pharming Healthcare received the United States Food and Drug Administration (USFDA) approval for Ruconest, a recombinant C1-esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with HAE.
Major players active in the global plasma protease C1-inhibitor treatment market are CSL Behring LLC, Pharming Group N.V., Takeda Pharmaceutical Company Limited, Ionis Pharmaceuticals, Inc., Pharming Technologies B.V., Centogene AG, BioCryst Pharmaceuticals, and KalVista Pharmaceuticals, Inc.
In April 2020, Pharming Group N.V. announced the encouraging results from five patients with confirmed COVID-19 (SARS-CoV-2) infections hospitalized with related severe pneumonia that were treated with RUCONEST (recombinant human C1 inhibitor) under a compassionate use program at the University Hospital Basel, Switzerland.
In June 2017, CSL Behring received the FDA approval for HAEGARDA (C1 Esterase Inhibitor Subcutaneous (Human)), the first and only subcutaneous therapy indicated for routine prophylaxis to prevent hereditary angioedema (HAE) attacks in adolescent and adult patients.
Other Related News:
Cholangiocarcinoma Market To Surpass US$ 429.6 Million By 2028
Post-Traumatic Stress Disorder Treatment Market To Surpass US$ 1,380.0 Million By 2028
Toxoplasmosis Treatment Drugs Market To Surpass US$ 3,996.7 Million By 2027
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- Coherent Market Insights
- Nirav Gokani